HRP20170848T1 - Kompozicije i metode za liječenje pluće hipertenzije - Google Patents
Kompozicije i metode za liječenje pluće hipertenzije Download PDFInfo
- Publication number
- HRP20170848T1 HRP20170848T1 HRP20170848TT HRP20170848T HRP20170848T1 HR P20170848 T1 HRP20170848 T1 HR P20170848T1 HR P20170848T T HRP20170848T T HR P20170848TT HR P20170848 T HRP20170848 T HR P20170848T HR P20170848 T1 HRP20170848 T1 HR P20170848T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- salt
- use according
- effective amount
- therapeutically effective
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 16
- 208000002815 pulmonary hypertension Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 12
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 claims 6
- 229960002414 ambrisentan Drugs 0.000 claims 6
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 6
- 229960000835 tadalafil Drugs 0.000 claims 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 5
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000021060 Pulmonary arterial hypertension associated with another disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (11)
1. Kompozicija za primjenu u liječenju plućne arterijske hipertenzije (PAH) kod ljudi, podešavanjem jednog ili više hemodinamičnih parametara ka normalnijem nivou u odnosu na osnovni, pri čemu kompozicija sadrži: terapijski efikasnu količinu ambrisentana ili njegove soli u kombinaciji sa terapijski efikasnom količinom tadalafila ili njegove soli,
Pri čemu je maseni odnos ambrisentana ili njegove soli u odnosu na tadalafil ili njegovu sol u opsegu od 1:1 do 1:10, i
Pri čemu je efikasnost administracije terapijski efikasne količine ambrisentana ili njegove soli u kombinaciji sa terapijski efikasnom količinom tadalafila ili njegove soli veća od zbira efikasnosti pojedinačne administracije svakog agensa.
2. Kompozicija za primjenu prema patentnom zahtjevu 1, pri čemi maseni odnos ambrisentana ili njegove soli u odnosu na tadalafil ili njegovu sol u opsegu od 1:2 do 1:5.
3. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu je kompozicija administrirana oralno ili parenteralno.
4. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu je kompozicija tableta ili kapsula.
5. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu je terapijski efikasna količina ambrisentana ili njegove soli od 1 mg do 100 mg dnevno.
6. Kompozicija za primjenu prema patentnom zahtjevu 5, pri čemu je terapijski efikasna količina ambrisentana ili njegove soli od 2 mg do 20 mg dnevno.
7. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu je terapijski efikasna količina tadalafila ili njegove soli od 5 mg do 500 mg dnevno.
8. Kompozicija za primjenu prema patentnom zahtjevu 7, pri čemu je terapijski efikasna količina tadalafila ili njegove soli od 10 mg do 100 mg dnevno.
9. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu je kompozicija administrirana jednom dnevno.
10. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu je PAH idiopatska PAH, familijarna PAH ili PAH povezana sa drugom bolešću ili stanjem.
11. Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, pri čemu je PAH u početku Klase II, III ili IV prema svjetskoj zdravstvenoj organizaciji.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39352910P | 2010-10-15 | 2010-10-15 | |
| US201161490454P | 2011-05-26 | 2011-05-26 | |
| US201161497475P | 2011-06-15 | 2011-06-15 | |
| PCT/US2011/056404 WO2012051559A2 (en) | 2010-10-15 | 2011-10-14 | Compositions and methods of treating pulmonary hypertension |
| EP11833507.4A EP2637664B1 (en) | 2010-10-15 | 2011-10-14 | Compositions and methods of treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170848T1 true HRP20170848T1 (hr) | 2017-08-25 |
Family
ID=45939010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170848TT HRP20170848T1 (hr) | 2010-10-15 | 2017-06-05 | Kompozicije i metode za liječenje pluće hipertenzije |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20120269898A1 (hr) |
| EP (2) | EP2637664B1 (hr) |
| JP (2) | JP5806320B2 (hr) |
| KR (2) | KR20150002876A (hr) |
| CN (1) | CN103458690B (hr) |
| AR (1) | AR083422A1 (hr) |
| AU (2) | AU2011315891B2 (hr) |
| BR (1) | BR112013008983A2 (hr) |
| CA (1) | CA2814518C (hr) |
| CY (1) | CY1119007T1 (hr) |
| DK (1) | DK2637664T3 (hr) |
| EA (2) | EA026074B1 (hr) |
| ES (1) | ES2627944T3 (hr) |
| HR (1) | HRP20170848T1 (hr) |
| HU (1) | HUE033346T2 (hr) |
| LT (1) | LT2637664T (hr) |
| MX (1) | MX346730B (hr) |
| NZ (2) | NZ610012A (hr) |
| PL (1) | PL2637664T3 (hr) |
| PT (1) | PT2637664T (hr) |
| RS (1) | RS56135B1 (hr) |
| SI (1) | SI2637664T1 (hr) |
| TW (1) | TWI542580B (hr) |
| WO (1) | WO2012051559A2 (hr) |
| ZA (1) | ZA201302746B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007333115B2 (en) | 2006-12-12 | 2013-01-10 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
| SI2637664T1 (sl) | 2010-10-15 | 2017-07-31 | Gilead Sciences, Inc. | Sestavki in postopki zdravljenja pljučne hipertenzije |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2014174529A2 (en) * | 2013-04-23 | 2014-10-30 | Hetero Research Foundation | Polymorphs of avanafil |
| WO2015069839A1 (en) * | 2013-11-06 | 2015-05-14 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
| CN105581990A (zh) * | 2014-08-27 | 2016-05-18 | 人福医药集团股份公司 | 安立生坦片剂及其制备方法 |
| CN107847462B (zh) | 2015-03-13 | 2021-08-10 | 美国印第安纳大学研究和技术公司 | 靶向cGMP相关的磷酸二酯酶以减少囊性肾病的囊肿形成和相关的材料与方法 |
| ES2875905T3 (es) | 2016-07-15 | 2021-11-11 | Acceleron Pharma Inc | Composiciones que comprenden polipéptidos ActRIIA para su uso en el tratamiento de la hipertensión pulmonar |
| WO2018081567A1 (en) * | 2016-10-27 | 2018-05-03 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
| WO2019010445A1 (en) * | 2017-07-07 | 2019-01-10 | The Regents Of The University Of Colorado, A Body Corporate | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION |
| AU2018397436A1 (en) * | 2017-12-26 | 2020-08-13 | Ftf Pharma Private Limited | Liquid oral formulations for PDE V inhibitors |
| CN109406688A (zh) * | 2018-09-28 | 2019-03-01 | 中国食品药品检定研究院 | 用于检测产品中违禁药品的标准样品 |
| IL293271A (en) * | 2019-11-29 | 2022-07-01 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary artery hypertension |
| CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
| KR102606504B1 (ko) * | 2020-04-10 | 2023-11-29 | 주식회사 대웅테라퓨틱스 | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 |
| CN112826944B (zh) * | 2021-01-29 | 2023-08-15 | 台州职业技术学院 | 一种安立生坦包合物及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| EP2295436A1 (de) | 1997-11-12 | 2011-03-16 | Bayer Schering Pharma AG | 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| WO2006007213A1 (en) | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| TW200621261A (en) * | 2004-08-26 | 2006-07-01 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| DK2013208T3 (da) | 2006-04-21 | 2011-08-15 | Pfizer Prod Inc | Pyridin[3,4-B]pyrazinoner |
| AU2007333115B2 (en) | 2006-12-12 | 2013-01-10 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
| CA2669535A1 (en) * | 2006-12-12 | 2008-06-19 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorders |
| CA2695259C (en) | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| SI2637664T1 (sl) | 2010-10-15 | 2017-07-31 | Gilead Sciences, Inc. | Sestavki in postopki zdravljenja pljučne hipertenzije |
-
2011
- 2011-10-14 SI SI201131190A patent/SI2637664T1/sl unknown
- 2011-10-14 JP JP2013534043A patent/JP5806320B2/ja not_active Expired - Fee Related
- 2011-10-14 CN CN201180060879.3A patent/CN103458690B/zh not_active Expired - Fee Related
- 2011-10-14 PT PT118335074T patent/PT2637664T/pt unknown
- 2011-10-14 LT LTEP11833507.4T patent/LT2637664T/lt unknown
- 2011-10-14 KR KR20147032816A patent/KR20150002876A/ko not_active Application Discontinuation
- 2011-10-14 MX MX2013004190A patent/MX346730B/es active IP Right Grant
- 2011-10-14 EP EP11833507.4A patent/EP2637664B1/en not_active Revoked
- 2011-10-14 EP EP16180914.0A patent/EP3106163A1/en not_active Withdrawn
- 2011-10-14 HU HUE11833507A patent/HUE033346T2/en unknown
- 2011-10-14 US US13/274,013 patent/US20120269898A1/en not_active Abandoned
- 2011-10-14 NZ NZ610012A patent/NZ610012A/en active IP Right Revival
- 2011-10-14 KR KR1020137012382A patent/KR20130069855A/ko active Search and Examination
- 2011-10-14 NZ NZ707213A patent/NZ707213A/en active IP Right Revival
- 2011-10-14 DK DK11833507.4T patent/DK2637664T3/en active
- 2011-10-14 ES ES11833507.4T patent/ES2627944T3/es active Active
- 2011-10-14 WO PCT/US2011/056404 patent/WO2012051559A2/en active Application Filing
- 2011-10-14 BR BR112013008983A patent/BR112013008983A2/pt not_active IP Right Cessation
- 2011-10-14 TW TW100137481A patent/TWI542580B/zh not_active IP Right Cessation
- 2011-10-14 PL PL11833507T patent/PL2637664T3/pl unknown
- 2011-10-14 EA EA201390428A patent/EA026074B1/ru active IP Right Revival
- 2011-10-14 RS RS20170640A patent/RS56135B1/sr unknown
- 2011-10-14 CA CA2814518A patent/CA2814518C/en not_active Expired - Fee Related
- 2011-10-14 AU AU2011315891A patent/AU2011315891B2/en active Active
- 2011-10-14 EA EA201691759A patent/EA201691759A1/ru unknown
- 2011-10-17 AR ARP110103833A patent/AR083422A1/es unknown
-
2013
- 2013-04-17 ZA ZA2013/02746A patent/ZA201302746B/en unknown
- 2013-11-13 US US14/079,548 patent/US9549926B2/en active Active
-
2015
- 2015-06-10 JP JP2015117196A patent/JP2015178528A/ja not_active Withdrawn
-
2016
- 2016-07-04 AU AU2016204638A patent/AU2016204638B2/en not_active Ceased
- 2016-08-09 US US15/232,570 patent/US20160346280A1/en not_active Abandoned
-
2017
- 2017-06-05 HR HRP20170848TT patent/HRP20170848T1/hr unknown
- 2017-06-22 CY CY20171100660T patent/CY1119007T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
| HRP20200665T1 (hr) | Bifenilsulfonamidni antagonist receptora za endotelin i angiotenzin ii za liječenje glomeruloskleroze i iga-inducirane nefropatije | |
| HRP20200060T1 (hr) | Nova uporaba | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
| CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| RS54648B1 (en) | COMBINED THERAPY WITH ANTITUMOR ALKALOID | |
| HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
| JP2011522896A5 (hr) | ||
| HRP20212030T1 (hr) | Kombinacija koja sadrži palbociklib i 6-(2,4-diklorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7h-benzo[7]anulen-2-karboksilnu kiselinu i njezina upotreba u liječenju raka | |
| HRP20210245T1 (hr) | Primjena fk506 za liječenje plućne arterijske hipertenzije | |
| BR112014014341A2 (pt) | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica | |
| JP2010531351A5 (hr) | ||
| EA201100409A1 (ru) | Замещенные производные триазолопиридазина | |
| AR084781A1 (es) | Composiciones que comprenden y metodos que utilizan inhibidores de los cotransportadores de sodio-glucosa 1 y 2 | |
| JP2009537554A5 (hr) | ||
| EA201492091A1 (ru) | Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину | |
| HRP20151347T1 (hr) | Nova kombinacija | |
| HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin | |
| RS53783B1 (en) | INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM | |
| HRP20171693T1 (hr) | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| JP2011516544A5 (hr) | ||
| WO2014006635A3 (en) | Solid oral compositions of silodosin | |
| JP2006517557A5 (hr) |